Buy this Article for $7.95

Have a coupon or promotional code? Enter it here:

When you buy this you'll get access to the ePub version, a downloadable PDF, and the ability to print the full article.

Keywords

canagliflozin, dapagliflozin, empagliflozin, sodium-glucose cotransporter-2 inhibitors, type 2 diabetes mellitus

 

Authors

  1. Novak, Lucia M. MSN, ANP-BC, BC-ADM, CDTC
  2. Kruger, Davida F. MSN, APN-BC, BC-ADM

Abstract

Abstract: Sodium-glucose cotransporter-2 inhibitors have a unique mechanism of action in the kidneys that causes glucosuria, which lowers plasma glucose. They are also associated with reduced body weight and BP, and a low incidence of hypoglycemia. This article reviews the pharmacologic profiles and clinical implications of canagliflozin, dapagliflozin, and empagliflozin.